EFG Asset Management Americas Corp. Cuts Stake in Natera, Inc. (NASDAQ:NTRA)

EFG Asset Management Americas Corp. lessened its stake in Natera, Inc. (NASDAQ:NTRA) by 11.4% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,153 shares of the medical research company’s stock after selling 1,689 shares during the quarter. EFG Asset Management Americas Corp.’s holdings in Natera were worth $1,860,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in NTRA. LRI Investments LLC acquired a new position in shares of Natera in the 4th quarter valued at $29,000. Rakuten Securities Inc. boosted its holdings in shares of Natera by 117.8% in the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 119 shares during the last quarter. ORG Partners LLC acquired a new position in shares of Natera in the 1st quarter valued at $32,000. TCTC Holdings LLC increased its position in Natera by 114.8% during the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock worth $33,000 after purchasing an additional 124 shares in the last quarter. Finally, ANTIPODES PARTNERS Ltd acquired a new stake in Natera during the 1st quarter worth approximately $40,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Activity at Natera

In other news, CFO Michael Burkes Brophy sold 3,045 shares of the firm’s stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $137.40, for a total transaction of $418,383.00. Following the completion of the sale, the chief financial officer owned 65,430 shares of the company’s stock, valued at approximately $8,990,082. This trade represents a 4.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Solomon Moshkevich sold 2,206 shares of the firm’s stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $139.81, for a total transaction of $308,420.86. Following the sale, the insider directly owned 126,059 shares of the company’s stock, valued at $17,624,308.79. The trade was a 1.72% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 42,844 shares of company stock worth $6,632,123 over the last three months. 7.60% of the stock is owned by corporate insiders.

Natera Trading Up 3.8%

NTRA stock opened at $140.96 on Thursday. Natera, Inc. has a twelve month low of $92.14 and a twelve month high of $183.00. The company has a market capitalization of $19.25 billion, a P/E ratio of -95.89 and a beta of 1.73. The firm has a 50 day simple moving average of $158.12 and a 200-day simple moving average of $156.45.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.09. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. The business had revenue of $501.83 million during the quarter, compared to the consensus estimate of $446.68 million. During the same quarter last year, the company earned ($0.56) earnings per share. The business’s quarterly revenue was up 36.5% compared to the same quarter last year. On average, research analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Evercore ISI raised shares of Natera to a “strong-buy” rating and set a $170.00 target price for the company in a research report on Monday. Wall Street Zen downgraded shares of Natera from a “hold” rating to a “sell” rating in a research report on Saturday, May 17th. Barclays increased their target price on shares of Natera from $160.00 to $190.00 and gave the stock an “overweight” rating in a research report on Friday, May 9th. Piper Sandler increased their target price on shares of Natera from $205.00 to $210.00 and gave the stock an “overweight” rating in a research report on Thursday, May 15th. Finally, UBS Group increased their target price on shares of Natera from $211.00 to $218.00 and gave the stock a “buy” rating in a research report on Friday, May 9th. One investment analyst has rated the stock with a sell rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $183.76.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.